Add to ORKGen e case of a patient with multiple sclerosis who developed wi a h point of view, interferon-γ (IFN-γ) plays an important role in granuloma formation of this disease [3]. Evidence for her lower limbs followed by ataxia in 2009. Magnetic res-onance imaging of her central nervous system revealed th
Preliminary studies have evaluated the effects of interferonβ formulations in the treatment of chron...
Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease ...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...
UNLABELLED: INTRODUCTION: With the increasing use of recombinant α and β interferon therapy for the...
Interferons are widely used platform therapies as disease-modifying treatment of patients with multi...
Multiple sclerosis (MS) is a chronic disease of the central nervous system, characterized by focal i...
Primary Sjören's syndrome with central nervous system involvement can clinically mimic multiple scle...
We present a case report of a 37-year-old woman with multiple sclerosis (MS) who developed ne-phroti...
Multiple sclerosis (MS) is a chronic and debilitating inflammatory autoimmune disorder of the centra...
Interferons are widely used platform therapies as disease-modifying treatment of patients with multi...
In late 2009, the today 32-year-old female experienced a feeling of numbness in her left arm and leg...
Interferon-alpha (IFN-α) has immunoregulatory functions in autoimmune inflammatory diseases. The goa...
Sarcoidosis is a multi-systemic inflammatory disease of unknown origin characterized by the presence...
We report the case of a 53-year-old woman treated for 8 years with Betaferon® (interferon-β-1b), who...
Interferon-β (IFN-β) drugs are considered to derive their beneficial effects on multiple sclerosis (...
Preliminary studies have evaluated the effects of interferonβ formulations in the treatment of chron...
Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease ...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...
UNLABELLED: INTRODUCTION: With the increasing use of recombinant α and β interferon therapy for the...
Interferons are widely used platform therapies as disease-modifying treatment of patients with multi...
Multiple sclerosis (MS) is a chronic disease of the central nervous system, characterized by focal i...
Primary Sjören's syndrome with central nervous system involvement can clinically mimic multiple scle...
We present a case report of a 37-year-old woman with multiple sclerosis (MS) who developed ne-phroti...
Multiple sclerosis (MS) is a chronic and debilitating inflammatory autoimmune disorder of the centra...
Interferons are widely used platform therapies as disease-modifying treatment of patients with multi...
In late 2009, the today 32-year-old female experienced a feeling of numbness in her left arm and leg...
Interferon-alpha (IFN-α) has immunoregulatory functions in autoimmune inflammatory diseases. The goa...
Sarcoidosis is a multi-systemic inflammatory disease of unknown origin characterized by the presence...
We report the case of a 53-year-old woman treated for 8 years with Betaferon® (interferon-β-1b), who...
Interferon-β (IFN-β) drugs are considered to derive their beneficial effects on multiple sclerosis (...
Preliminary studies have evaluated the effects of interferonβ formulations in the treatment of chron...
Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease ...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...